KEY TAKEAWAYS
- The REALYSA observational study aimed to evaluate the HRQoL in newly diagnosed patients with lymphoma.
- The study established detailed HRQoL profiles, aiding future interpretation of HRQoL results in lymphoma research.
Recent advancements in lymphoma treatment highlight the importance of assessing patients’ health-related quality of life (HRQoL). Comprehensive information regarding the lymphoma-specific HRQoL profile at the time of diagnosis is lacking. Understanding HRQoL is crucial in both clinical research and routine practice.
Amélie Anota and the team aimed to address the information gap by evaluating HRQOL in newly diagnosed lymphoma patients.
Researchers assessed HRQoL at diagnosis for 3922 adult patients with newly diagnosed lymphomas, including high-grade (HG, n=1994), low-grade (LG, n=1053) non-Hodgkin Lymphomas (NHL), and Hodgkin lymphoma (HL) (n=875). These patients were part of the REal world dAta in LYmphoma and Survival in Adults (REALYSA, NCT03869619) study in France.
They used 3 validated EORTC questionnaires—QLQ-NHL-HG20 for NHL-HG, QLQ-NHL-LG20 for NHL-LG, and QLQ-HL27 for HL—to evaluate disease-specific HRQoL aspects.
Results indicated that in the REALYSA cohort, the completion rates for the questionnaires were high, ranging from 84% for QLQ-HG29 to 88% for QLQ-HL27. Impaired global health status was found in 67% of patients with T-cell NHL, 62% of patients with diffuse large B-cell lymphoma (DLBCL), 61% of patients with Burkitt lymphoma, 53% of patients with Hodgkin Lymphoma, 49% of patients with marginal zone lymphoma (MZL), 48% of patients with mantle cell lymphoma (MCL), and 47% of patients with follicular lymphoma (FL).
Multivariable regression analyses showed that gender, performance status, and B symptoms were linked with all HRQoL dimensions, though age and stage had varying effects among the subtypes.
The study concluded that a detailed HRQoL profile for newly diagnosed patients with lymphoma was established. This analysis may improve the interpretation of HRQoL results in future research using the newly validated EORTC lymphoma-specific questionnaires.
The study was sponsored by Hospices Civils de Lyon.
Source: https://pubmed.ncbi.nlm.nih.gov/39002346/
Clinical Trial: https://clinicaltrials.gov/study/NCT03869619
Anota A, Basset M, Charton E, et al. (2024). “Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort.” Eur J Cancer. 2024 Sep;208:114210. doi: 10.1016/j.ejca.2024.114210. Epub 2024 Jul 4. PMID: 39002346.
